{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.176","meta":{"versionId":"6","lastUpdated":"2023-06-23T16:14:24.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"American Society of Clinical Oncology Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-06-23"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.176","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.1444.3.176"}],"version":"20210319","name":"ImmunotherapyAdministration","title":"Immunotherapy Administration","status":"active","experimental":false,"date":"2021-03-19T01:00:22-04:00","publisher":"American Society of Clinical Oncology Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for the procedure of immunotherapy administration.),(Data Element Scope: This value set may use a model element related to Procedure.),(Inclusion Criteria: Includes concepts that represent a procedure for immunotherapy administration.),(Exclusion Criteria: Excludes CAR T-cell and TIL therapies.)","compose":{"include":[{"system":"http://www.cms.gov/Medicare/Coding/ICD10","concept":[{"code":"XW03351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW033C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW04351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW043C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW23346","display":"Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6"},{"code":"XW23376","display":"Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6"},{"code":"XW24346","display":"Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6"},{"code":"XW24376","display":"Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6"}]}]},"expansion":{"identifier":"urn:uuid:e59fba12-421a-4f26-ac94-cd1ef5e43e8f","timestamp":"2023-12-11T01:19:01-05:00","total":0}}